Analysts forecast that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will announce ($2.42) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for GW Pharmaceuticals PLC-‘s earnings. The highest EPS estimate is ($2.13) and the lowest is ($2.64). GW Pharmaceuticals PLC- posted earnings of ($2.18) per share in the same quarter last year, which would indicate a negative year over year growth rate of 11%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, November 27th.
On average, analysts expect that GW Pharmaceuticals PLC- will report full year earnings of ($9.13) per share for the current year, with EPS estimates ranging from ($10.08) to ($8.26). For the next year, analysts forecast that the business will post earnings of ($6.75) per share, with EPS estimates ranging from ($9.12) to ($2.28). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover GW Pharmaceuticals PLC-.
GWPH has been the topic of several research reports. Piper Jaffray Companies reissued an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Monday, November 5th. Morgan Stanley set a $197.00 target price on GW Pharmaceuticals PLC- and gave the stock an “overweight” rating in a research note on Friday, September 7th. BidaskClub lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $168.00 target price on the stock in a research note on Wednesday, October 10th. Finally, Bank of America reissued a “buy” rating and set a $197.00 target price (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a research note on Friday, September 28th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and a consensus target price of $187.63.
Institutional investors and hedge funds have recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at approximately $109,000. Envestnet Asset Management Inc. acquired a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at approximately $119,000. Cowen Prime Services LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 708.0% in the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 885 shares during the period. Sowell Financial Services LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 3rd quarter valued at approximately $204,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of GW Pharmaceuticals PLC- in the 3rd quarter valued at approximately $205,000. 69.92% of the stock is owned by institutional investors and hedge funds.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Featured Article: Market Capitalization – What it Means for Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.